"The closing of the PVP II LP is a testament to Phoenix Venture Partners investment strategy in advanced material innovation. This investment has exposed Pfizer to significant and strategically important technologies that would not have been on our radar screen. We are looking forward to a continued productive relationship with PVP II.”

- Barbara Dalton, Vice President, Venture Capital, Worldwide Business Development & Innovation at Pfizer, Inc.

Phoenix
2017-04-03T14:12:36+00:00

- Barbara Dalton, Vice President, Venture Capital, Worldwide Business Development & Innovation at Pfizer, Inc.

"The closing of the PVP II LP is a testament to Phoenix Venture Partners investment strategy in advanced material innovation. This investment has exposed Pfizer to significant and strategically important technologies that would not have been on our radar screen. We are looking forward to a continued productive relationship with PVP II.”